Revenue and Profitability - Revenue for the six months ended September 30, 2025, was HK$55,145,000, a decrease of 22.4% compared to HK$70,900,000 for the same period in 2024[12] - Gross profit for the same period was HK$8,485,000, down 49.5% from HK$16,805,000 in 2024[12] - Operating profit increased to HK$2,711,000, compared to HK$794,000 in the previous year, marking a significant improvement[12] - Profit for the period was HK$2,517,000, a turnaround from a loss of HK$1,901,000 in 2024[12] - Basic earnings per share for the period was 0.28 HK cents, compared to a loss of 0.92 HK cents per share in the previous year[12] - Total comprehensive income for the period was HK$1,941,000, compared to a loss of HK$5,356,000 in the same period last year[14] Financial Position - As of September 30, 2025, total assets less current liabilities amounted to HK$229,119,000, a decrease from HK$240,451,000 as of March 31, 2025, representing a decline of approximately 4.9%[15] - Current assets totaled HK$221,363,000, slightly down from HK$226,998,000, indicating a decrease of about 2.5%[15] - Net current assets were reported at HK$168,810,000, down from HK$177,275,000, reflecting a decrease of approximately 4.8%[15] - Non-current liabilities decreased to HK$71,301,000 from HK$84,574,000, showing a reduction of about 15.6%[17] - The company's equity attributable to owners increased to HK$140,880,000 from HK$139,283,000, marking a growth of about 1.1%[17] - Cash and cash equivalents rose to HK$57,459,000 from HK$47,773,000, indicating an increase of approximately 20.5%[15] - The company’s total equity reached HK$157,818,000, up from HK$155,877,000, reflecting an increase of about 1.2%[17] Cash Flow and Investments - Net cash used in operating activities was HK$8,121,000, a significant improvement compared to a net cash usage of HK$3,942,000 in the previous year[20] - For the six months ended September 30, 2025, net cash generated from investing activities was HK$220,000, a slight decrease from HK$230,000 in the same period of 2024[21] - The net cash generated from financing activities for the same period was HK$2,026,000, down from HK$13,550,000 in 2024, indicating a significant reduction in financing inflows[21] - The company raised new bank loans amounting to HK$5,995,000 during the period, compared to HK$1,090,000 in the previous year[21] - The company reported a net increase in cash and cash equivalents of HK$10,367,000, compared to HK$9,838,000 in the prior year, representing an increase of approximately 5.4%[21] Segment Performance - The company has three operating segments: jewellery business, skincare business, and strategic investment in real estate financial assets[33] - The jewellery business generated revenue of HK$43,548,000, while the skincare business contributed HK$11,597,000, indicating a significant drop in both segments compared to the previous year[38][41] - Segment profit for the jewellery business was HK$401,000, while the skincare business reported a loss of HK$6,716,000, leading to a total segment loss of HK$6,375,000 for the period[38] - The skincare segment experienced a significant loss, with a segment profit of HK$7,421,000 in the previous year turning into a loss of HK$6,716,000 this year[41] Expenses and Cost Management - Administrative expenses decreased slightly to HK$15,683,000 from HK$16,236,000, showing cost control efforts[12] - Employee benefit expenses for the period were HK$9,209,000, slightly lower than HK$9,368,000 in the previous year[59] - Selling and administrative expenses decreased by approximately HK$1.3 million or 6.7% to approximately HK$18.2 million in HY25, primarily due to reduced revenue[176] Credit and Risk Management - The company reported a provision for expected credit loss of HK$1,953,000, up from HK$142,000 in 2024, reflecting increased caution in financial management[12] - The provision for expected credit losses on trade receivables was HK$54,000, down from HK$362,000 in 2024, indicating improved credit risk management[59] Shareholder and Equity Information - The weighted average number of ordinary shares in issue during the period was 772,391,072, up from 679,328,374 in the previous year[73] - The Group recorded a profit attributable to owners of approximately HK$2.2 million in HY25, compared to a loss of approximately HK$6.2 million in HY24, mainly due to gains on the change in fair value of convertible bonds[177] - A total of 119,863,013 Conversion Shares were issued at a conversion price of HK$0.2628 per share, representing approximately 13.43% of the enlarged issued share capital[116] Strategic Initiatives and Future Plans - The company continues to focus on market expansion and new product development as part of its strategic initiatives[12] - The Group plans to expand its jewellery product offerings to mainland China and other Asian markets, where demand remains strong[139] - The Company aims to maintain operational efficiency and productivity while actively participating in jewellery fairs and events to enhance its customer base[140] - The company entered into a strategic cooperation framework agreement with Youhuan Bio to establish a circRNA technology R&D platform, although the timing and amount of investment have not been determined[165]
佰金生命科学(01466) - 2026 - 中期财报